BMT CTN 1102: RIC Allogeneic HSCT vs Non-HSCT Therapy in Patients 50-75 Yrs With Higher-risk MDS

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Results of this open-label phase II study show that undergoing HSCT leads to improved outcomes in older patients with high-risk MDS when compared with no HSCT.
Format: Microsoft PowerPoint (.ppt)
File Size: 381 KB
Released: December 10, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech, Inc.
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Related Content

In this commentary from Clinical Care Options (CCO), Asim V. Farooq, MD and Joann Kang, MD, provide guidance on monitoring and mitigating ocular toxicities associated with antibody-drug conjugates

Asim V. Farooq, MD Joann Kang, MD Released: January 20, 2022

Downloadable slideset from a live webinar from Clinical Care Options (CCO) on the diagnosis and staging of light-chain amyloidosis

Shaji K. Kumar, MD Released: January 18, 2022

Downloadable slideset from a live webinar from Clinical Care Options (CCO) on the initial management of light-chain amyloidosis

Vaishali Sanchorawala, MD Released: January 18, 2022

Downloadable slideset from a live webinar from Clinical Care Options (CCO) on the management of light-chain amyloidosis at relapse

Ankit Kansagra, MD Released: January 18, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings